Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Remacha, A.
Right arrow Articles by Aventin, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Remacha, A.
Right arrow Articles by Aventin, A
Haematologica, Vol 91, Issue 5, 719-720
Copyright © 2006 by Ferrata Storti Foundation

Letter

Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis

AF Remacha, JF Nomdedeu, G Puget, C Estivill, MP Sarda, C Canals, and A Aventin

The JAK2/V617F mutation has been noted in essential thrombocytemia. We investigated 19 cases with refractory anemia with ringed sideroblasts (RARS), including three RARS with thrombocytosis (RARS-T). Only the RARS-T patients showed this mutation. More cases need to be analyzed to determine the prevalence of the JAK2/V617F mutation in RARS-T.


This article has been cited by other articles:


Home page
 haematolHome page
M. Cazzola
Molecular basis of thrombocytosis
Haematologica, May 1, 2008; 93(5): 646 - 648.
[Full Text] [PDF]

Home page
 haematolHome page
L. Malcovati and M. Cazzola
Myelodysplastic/myeloproliferative disorders
Haematologica, January 1, 2008; 93(1): 4 - 6.
[Full Text] [PDF]

Home page
 haematolHome page
A. H. Schmitt-Graeff, S.-S. Teo, M. Olschewski, F. Schaub, S. Haxelmans, A. Kirn, P. Reinecke, U. Germing, and R. C. Skoda
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
Haematologica, January 1, 2008; 93(1): 34 - 40.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. D. Nimer
MDS: A Stem Cell Disorder--But What Exactly Is Wrong with the Primitive Hematopoietic Cells in This Disease?
Hematology, January 1, 2008; 2008(1): 43 - 51.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
E. Hellstrom-Lindberg and M. Cazzola
The Role of JAK2 Mutations in RARS and Other MDS
Hematology, January 1, 2008; 2008(1): 52 - 59.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Tefferi, J. Thiele, A. Orazi, H. M. Kvasnicka, T. Barbui, C. A. Hanson, G. Barosi, S. Verstovsek, G. Birgegard, R. Mesa, et al.
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
Blood, August 15, 2007; 110(4): 1092 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Gattermann, J. Billiet, R. Kronenwett, E. Zipperer, U. Germing, F. Nollet, A. Criel, and D. Selleslag
High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600 x 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable
Blood, February 1, 2007; 109(3): 1334 - 1335.
[Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.